Roivant Sciences Ltd. (ROIV)
NEUTRALFundamental
34
Kurs
$36.47
Marktkapitalisierung
$26.29B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$8M
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$-266M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$-759M
Gesamtes Eigenkapital
$4.53B
Gesamtverbindlichkeiten
$416M
Current Ratio
16.72
Zinsdeckungsgrad
-
Schulden/EBITDA
-
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$41.82
Aktueller Kurs
$36.47
Sicherheitsmarge
+12.8%
Innerer-Wert-Spanne
$39.73 - $43.91
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
-
ROE
-6.6%
P/B-Verhältnis
6.21
P/FCF
-
Bruttomarge
-
ROIC
-9.4%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
-9.4%
WACC
10.5%
ROIC − WACC
-19.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (7)
- EPS shows upward trend
- Price CAGR 23.63%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 89% Buy
- Share Dilution -22.5%
Nicht bestanden (11)
- ROIC -9.4%
- P/B Ratio 6.21
- Operating Margin -7914.8%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -6.1%
- Revenue Growth 5Y -19.1%
- Earnings Surprise avg -2.3%
- Net Margin Trend -3535.0% vs -2111.8%
- Piotroski F-Score 1/9
Nicht verfügbar (9)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Ernsthafte finanzielle Bedenken
Gewinnqualität
Niedrige Qualität: Rechnungslegung prüfen
Aktienverwässerung
Aktienrückkäufe. Aktionärsfreundlich
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. Matthew Gline | CEO & Director | 41 |
| Dr. Eric Venker M.D., Pharm.D. | President & CEO of Immunovant | 38 |
| Dr. Mayukh Sukhatme M.D. | President, Chief Investment Officer & Director | 49 |
| Dr. Frank M. Torti M.B.A., M.D. | President & Vant Chair | 46 |
| Mr. Richard Pulik | Chief Financial Officer | 45 |
| Ms. Jennifer Humes | Chief Accounting Officer | 44 |
| Mr. Ian Rosenblum | Chief Information Officer | - |
| Mr. Sam Kaplan | General Counsel | - |
| Ms. Kelly Graff | Head of People | - |
| Mr. Alex Gasner | Executive Vice President of Roivant Health | - |
Prüfungsrisiko
5
Vorstandsrisiko
7
Vergütungsrisiko
10
Aktionärsrechterisiko
4
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for ROIV, sourced from Markets Gazette.
- 19d agoPOSITIVERoivant Expects FDA to Approve First Major Drug
Roivant Sciences Ltd. is anticipating FDA approval for its novel drug targeting a severe skin condition, with a market launch projected for September. CEO Matt Gline expressed optimism about the drug's potential. This development represents a significant milestone for Roivant, potentially unlocking a new revenue stream and validating its research and development pipeline. Investors will be closely watching the official FDA decision, as approval could lead to substantial growth and market share gains in the dermatology sector.
via Markets Gazette